Lichen planus pigmentosum (LPP) is an uncommon variant of Lichen plan clinically characterized by lichenoid lesions of photoexposed. Pruritus may be present in the early active phase, and the disease often has a prolonged clinical course [1]. There is no effective treatment for LPP. Various therapeutic modalities such as topical tacrolimus, topical and systemic corticosteroids, high-dose vitamin A and lasers have been tried with no prometting results [2-6]. Isotretinoin is a first generation retinoid discovered in 1952 and was approved by the FDA for the treatment of nodulokystic acne in 1982. Isotretinoin anti-inflammatory properties have allowed it to be used in disorders other than acne. Its adverse effects range from simple xerosis to teratogenicity. There have been a few isolated reports of isotretinoin (topical/systemic) efficiency in the treatment of LPP but its role in LPP has not yet been totally elucidated [7,8]. The objective of this study was to evaluate the efficiency and safety of low-dose isotretinoin in the treatment of LPP
{"title":"Retinoids in Lichen Planus Pigmentogenes","authors":"","doi":"10.33140/ijced.08.02.03","DOIUrl":"https://doi.org/10.33140/ijced.08.02.03","url":null,"abstract":"Lichen planus pigmentosum (LPP) is an uncommon variant of Lichen plan clinically characterized by lichenoid lesions of photoexposed. Pruritus may be present in the early active phase, and the disease often has a prolonged clinical course [1]. There is no effective treatment for LPP. Various therapeutic modalities such as topical tacrolimus, topical and systemic corticosteroids, high-dose vitamin A and lasers have been tried with no prometting results [2-6]. Isotretinoin is a first generation retinoid discovered in 1952 and was approved by the FDA for the treatment of nodulokystic acne in 1982. Isotretinoin anti-inflammatory properties have allowed it to be used in disorders other than acne. Its adverse effects range from simple xerosis to teratogenicity. There have been a few isolated reports of isotretinoin (topical/systemic) efficiency in the treatment of LPP but its role in LPP has not yet been totally elucidated [7,8]. The objective of this study was to evaluate the efficiency and safety of low-dose isotretinoin in the treatment of LPP","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"210 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126431602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Sharquie, Dr. Waqas S. Abdulwahhab, Mohommed Al Abadie
Background Solar keratosis, also known as actinic keratosis or senile keratosis, is a skin condition that results from repeated sun exposure and damage, particularly in middle-aged and elderly individuals. It is characterized by rough, scaly, and warty lesions that may be pigmented, erythematous, or both, and can occur as macules, patches, or plaques. Solar keratosis lesions are most commonly found on the face and scalp and can be associated with basal cell carcinoma but not squamous cell carcinoma or solar keratosis of the lower lip. It is more prevalent in fair-skinned individuals who live in areas with high UV radiation, particularly those over 40 years of age. Objective The aim of this study was to document all instances of solar keratosis in patients with Fitzpatrick skin types III and IV, using a comprehensive clinical evaluation. Patients with xeroderma pigmentosum were excluded from the study. The study was conducted between 2014-2021 and involved 80 patients with solar keratosis and 43 patients with squamous cell carcinoma of the lower lips. Demographic information, complete medical history, and clinical evaluations were collected, and biopsies were performed on select patients for histopathological confirmation. This was a cross-sectional descriptive study. Results The study included 80 patients with solar keratosis, with ages ranging from 50 to 65 years and a mean age of 58 years. Of these patients, 41 (51.3%) were male and 39 (48.7%) were female. The lesions were predominantly located on the face, affecting 58 (72.5%) patients, while 12 (15%) patients had lesions on both the face and scalp, 4 (5%) had lesions on the scalp, forearms, and hands, and 2 (2.5%) had lesions on the eye sclera. Multiple lesions were present in 62 (77.5%) cases, and a butterfly-shaped distribution on the cheeks was observed in 18 (22.5%) patients (8 females and 10 males). The study identified rough, scaly, warty, and pigmented-erythematous rashes in the form of macules, patches, and plaques as the most common characteristics of the solar keratosis lesions. Among the 80 patients with solar keratosis, only 4 (5%) had the condition on their lower lip, and none of them had squamous cell carcinoma. In contrast, basal cell carcinoma was observed in 50 (62.5%) of patients affecting both faces and scalps, but no squamous cell carcinoma was detected. Among the 43 patients with squamous cell carcinoma of the lower lips, 2 (4.65%) had associated solar keratosis of the face. The age range of the patients with squamous cell carcinoma was 20-78 years, with a mean of 50 years, and the majority (83.7%) were males.Solar keratosis is a common condition affecting the face and scalp of elderly patients of both sexes, and is often found in conjunction with basal cell carcinoma but not squamous cell carcinoma. This association between solar keratosis and basal cell carcinoma is coincidental rather than causal, as both are common conditions that often occur together. Importantly, so
{"title":"Clinical Evaluation of 80 Patients with Solar Keratosis Vs 43 Patients with Squamous Cell Carcinoma of Lower Lips: Basal Cell Carcinoma is a Commonly Associated Disease with no Causal Relation","authors":"K. Sharquie, Dr. Waqas S. Abdulwahhab, Mohommed Al Abadie","doi":"10.33140/ijced.08.02.02","DOIUrl":"https://doi.org/10.33140/ijced.08.02.02","url":null,"abstract":"Background Solar keratosis, also known as actinic keratosis or senile keratosis, is a skin condition that results from repeated sun exposure and damage, particularly in middle-aged and elderly individuals. It is characterized by rough, scaly, and warty lesions that may be pigmented, erythematous, or both, and can occur as macules, patches, or plaques. Solar keratosis lesions are most commonly found on the face and scalp and can be associated with basal cell carcinoma but not squamous cell carcinoma or solar keratosis of the lower lip. It is more prevalent in fair-skinned individuals who live in areas with high UV radiation, particularly those over 40 years of age. Objective The aim of this study was to document all instances of solar keratosis in patients with Fitzpatrick skin types III and IV, using a comprehensive clinical evaluation. Patients with xeroderma pigmentosum were excluded from the study. The study was conducted between 2014-2021 and involved 80 patients with solar keratosis and 43 patients with squamous cell carcinoma of the lower lips. Demographic information, complete medical history, and clinical evaluations were collected, and biopsies were performed on select patients for histopathological confirmation. This was a cross-sectional descriptive study. Results The study included 80 patients with solar keratosis, with ages ranging from 50 to 65 years and a mean age of 58 years. Of these patients, 41 (51.3%) were male and 39 (48.7%) were female. The lesions were predominantly located on the face, affecting 58 (72.5%) patients, while 12 (15%) patients had lesions on both the face and scalp, 4 (5%) had lesions on the scalp, forearms, and hands, and 2 (2.5%) had lesions on the eye sclera. Multiple lesions were present in 62 (77.5%) cases, and a butterfly-shaped distribution on the cheeks was observed in 18 (22.5%) patients (8 females and 10 males). The study identified rough, scaly, warty, and pigmented-erythematous rashes in the form of macules, patches, and plaques as the most common characteristics of the solar keratosis lesions. Among the 80 patients with solar keratosis, only 4 (5%) had the condition on their lower lip, and none of them had squamous cell carcinoma. In contrast, basal cell carcinoma was observed in 50 (62.5%) of patients affecting both faces and scalps, but no squamous cell carcinoma was detected. Among the 43 patients with squamous cell carcinoma of the lower lips, 2 (4.65%) had associated solar keratosis of the face. The age range of the patients with squamous cell carcinoma was 20-78 years, with a mean of 50 years, and the majority (83.7%) were males.Solar keratosis is a common condition affecting the face and scalp of elderly patients of both sexes, and is often found in conjunction with basal cell carcinoma but not squamous cell carcinoma. This association between solar keratosis and basal cell carcinoma is coincidental rather than causal, as both are common conditions that often occur together. Importantly, so","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"2021 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117222567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Exposure to hypoxia may experience damage to the heart, brain, lungs and other organs due to the low inspired O2. The improvement of endurance of human in resisting hypoxia and reducing hypoxia‑induced organ damage is an urgent problem to be solved. WYY026B is a honokiol derivatives by structural modification, and exhibits very potent pharma‑ cological activities and medicinal properties in brain ischemia/reperfusion (I/R) injury. Methods We used hypoxia model cerebral I/R model to identify the anti-hypoxia effect of WYY026B. High performance liquid chromatograph and immunofluorescence assay were used to detect the relationship between WYY026B and Red blood cells (RBCs). Interaction between WYY026B and hemoglobin (Hb) were validated by surface plasmon resonance assay (SPR). Results We demonstrated that WYY026B increased arterial oxygen saturation (SaO2) and arterial partial pressure of oxygen un‑ der hypoxia stress to improve the hypoxia tolerance. Blood gas analysis showed that WYY026B significantly decreased cervical venous SaO2 and increased arteriovenous oxygen partial pressure difference in I/R model. Nissl´s staining in‑ dicated that WYY026B significantly reduced the degree of hypoxia in brain tissue. A series of tests in vitro revealed that WYY026B could combine with RBCs. SPR assays showed that WYY026B interacted with Hb. Conclusion Overall, WYY026B maybe a new drug to enhance the ability of Hb to carry oxygen and to protect brain from the hypoxia injury
{"title":"The Anti-Hypoxia Protective Effect of WYY026B by Interacting with Hemoglobin in Red Blood Cells","authors":"","doi":"10.33140/ijced.08.02.01","DOIUrl":"https://doi.org/10.33140/ijced.08.02.01","url":null,"abstract":"Background Exposure to hypoxia may experience damage to the heart, brain, lungs and other organs due to the low inspired O2. The improvement of endurance of human in resisting hypoxia and reducing hypoxia‑induced organ damage is an urgent problem to be solved. WYY026B is a honokiol derivatives by structural modification, and exhibits very potent pharma‑ cological activities and medicinal properties in brain ischemia/reperfusion (I/R) injury. Methods We used hypoxia model cerebral I/R model to identify the anti-hypoxia effect of WYY026B. High performance liquid chromatograph and immunofluorescence assay were used to detect the relationship between WYY026B and Red blood cells (RBCs). Interaction between WYY026B and hemoglobin (Hb) were validated by surface plasmon resonance assay (SPR). Results We demonstrated that WYY026B increased arterial oxygen saturation (SaO2) and arterial partial pressure of oxygen un‑ der hypoxia stress to improve the hypoxia tolerance. Blood gas analysis showed that WYY026B significantly decreased cervical venous SaO2 and increased arteriovenous oxygen partial pressure difference in I/R model. Nissl´s staining in‑ dicated that WYY026B significantly reduced the degree of hypoxia in brain tissue. A series of tests in vitro revealed that WYY026B could combine with RBCs. SPR assays showed that WYY026B interacted with Hb. Conclusion Overall, WYY026B maybe a new drug to enhance the ability of Hb to carry oxygen and to protect brain from the hypoxia injury","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115332095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction Sensitive skin is common in acne patients. In these subjects, it is important to adopt, whenever possible, a multi-product holistic protocol approach to reduce acne lesions, improve skin barrier function and ensure good tolerability profile with the final goal of good treatment adherence. Study Aim The aim of this clinical trial was to evaluate the tolerability and efficacy of a cosmetic protocol regimen in improving facial skin conditions in subjects with sensitive and acne-prone skin. The cosmetic holistic treatment was based on the use of a specific cleanser (Biretix Cleanser) with antimicrobial activity (biopep15); a topical anti-acne product in gel formulation containing two retinoid molecules (RetinSpere® technology: hydroxy pinacolone retinoate and retinol encapsulated in glycospheres) with additional anti-inflammatory (niacinamide), antibacterial (biopep15) and keratolytic (glycolic and salicylic) activities; and a cream for adjuvant skin care (Biretix Hydramat) featuring hydrating, seboregulating and barrier renewal actives.The use of this complete cosmetic protocol (based on purify, treat, and care steps) could be particularly effective in the treatment of subjects with sensitive and acne-prone skin where treatment products can often cause excess dryness and irritation leading to lack of patient compliance and adherence. Subjects and Methods The study was carried out on 20 women, aged 18-45 years, with sensitive and acne prone skin. Subjects cleansed and applied the adjuvant cream twice daily, morning and evening, and used the treatment cream in the evening and the cream for the skin care both in the morning and in the evening. The primary outcome of the study was the evaluation of the tolerability and acceptability of the cosmetic treatment regimen. Secondary outcomes were the evaluation of the efficacy of the regimen on acne lesions, sebum production, skin barrier function and skin hydration. Instrumental evaluations were carried out by means of non-invasive bioengineering techniques. Skin sebum levels were measured using Sebumeter® method (Sebumeter 815, Courage+Khazak GmbH). Trans epidermal water loss (TEWL) was measured by means of the internationally recognized TEWAMETER® method (Tewameter 300® Courage+Khazaka, electronic GmbH). Skin moisturization was evaluated by means of Corneometer®. Visia® pictures were taken at baseline and after treatments to evaluate acne lesions. Results The Tested products were well tolerated by all the subjects. No adverse reactions or adverse events related to the cosmetic treatment were observed during the study. A significant reduction was observed in sebum production (-30%) at the end of treatment period. Skin barrier function significantly improved: TEWL was reduced by 9% at week 6. The products significantly improved skin moisturization with an increase of 20% at week 6 in comparison with baseline. Finally, this regimen significantly reduced non inflammatory acne lesions by 26% at wee
{"title":"Association between Anthropometric indices and Cardiometabolic Risk Factors among Women with Primary Infertility","authors":"","doi":"10.33140/ijced.08.01.03","DOIUrl":"https://doi.org/10.33140/ijced.08.01.03","url":null,"abstract":"Introduction Sensitive skin is common in acne patients. In these subjects, it is important to adopt, whenever possible, a multi-product holistic protocol approach to reduce acne lesions, improve skin barrier function and ensure good tolerability profile with the final goal of good treatment adherence. Study Aim The aim of this clinical trial was to evaluate the tolerability and efficacy of a cosmetic protocol regimen in improving facial skin conditions in subjects with sensitive and acne-prone skin. The cosmetic holistic treatment was based on the use of a specific cleanser (Biretix Cleanser) with antimicrobial activity (biopep15); a topical anti-acne product in gel formulation containing two retinoid molecules (RetinSpere® technology: hydroxy pinacolone retinoate and retinol encapsulated in glycospheres) with additional anti-inflammatory (niacinamide), antibacterial (biopep15) and keratolytic (glycolic and salicylic) activities; and a cream for adjuvant skin care (Biretix Hydramat) featuring hydrating, seboregulating and barrier renewal actives.The use of this complete cosmetic protocol (based on purify, treat, and care steps) could be particularly effective in the treatment of subjects with sensitive and acne-prone skin where treatment products can often cause excess dryness and irritation leading to lack of patient compliance and adherence. Subjects and Methods The study was carried out on 20 women, aged 18-45 years, with sensitive and acne prone skin. Subjects cleansed and applied the adjuvant cream twice daily, morning and evening, and used the treatment cream in the evening and the cream for the skin care both in the morning and in the evening. The primary outcome of the study was the evaluation of the tolerability and acceptability of the cosmetic treatment regimen. Secondary outcomes were the evaluation of the efficacy of the regimen on acne lesions, sebum production, skin barrier function and skin hydration. Instrumental evaluations were carried out by means of non-invasive bioengineering techniques. Skin sebum levels were measured using Sebumeter® method (Sebumeter 815, Courage+Khazak GmbH). Trans epidermal water loss (TEWL) was measured by means of the internationally recognized TEWAMETER® method (Tewameter 300® Courage+Khazaka, electronic GmbH). Skin moisturization was evaluated by means of Corneometer®. Visia® pictures were taken at baseline and after treatments to evaluate acne lesions. Results The Tested products were well tolerated by all the subjects. No adverse reactions or adverse events related to the cosmetic treatment were observed during the study. A significant reduction was observed in sebum production (-30%) at the end of treatment period. Skin barrier function significantly improved: TEWL was reduced by 9% at week 6. The products significantly improved skin moisturization with an increase of 20% at week 6 in comparison with baseline. Finally, this regimen significantly reduced non inflammatory acne lesions by 26% at wee","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130098626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pyogenic granuloma (PG) is a benign vascular neoplasm, which exhibits several clinical features suggestive of reactive neovascularization. It is common in children and young adults, with a slight predominance in women. PG may occur spontaneously or may result from local trauma. Histologically the lesion of pyogenic granuloma. Proliferating capillaries are often grouped into lobules by dense fibrous bands, hence the synonym lobular capillary hemangioma The lesion is often clutched by an epithelial. On dermoscopy Red homogenous areas intersected by whitish lines – most common in pyogenic granuloma. There are no standard guidelines for the management of PG So invasive or noninvasive approach. Key Message Topical timolol therapy may be the first line of treatment for infected pyogenic granulomas; no adverse systemic effects were reported, over delicate areas like the nose - face on young children, older people, where invasive methods are not preferred, topical timolol may be a therapy option. Objectives to determine whether topical timolol is safe and effective for treating Infected pyogenic granulomas.. Methods We report an A 15-year-old female patient came in with a history of a single, rapidly expanding red lesion on the left side of her nose that had been developing in size for more than a month and was accompanied by minor pain and itching. In addition to unilateral purulent discharge from inside the nose, there was a history of a mild bleeding episode a few days before to consultation. The patient disclosed that she had her nose pierced a month earlier. Suggesting that infected pyogenic granuloma (PG) may coexist. The patient was prescribed timolol twice daily and trimethoprim/polymyxin four times daily with a pyogenic granuloma as the presumptive diagnosis. Results Significant improvement was noted with topical timolol with reduction of the lesion size decrease of bleeding tendency and here symptoms had resolved. Limitations we observed Effects of treatment only in 8 weeks. Conclusion Infected pyogenic granulomas may benefit from topical timolol therapy Longer studies are needed to evaluate resolution and recurrence Rates.
{"title":"Timolol For the Treatment of Infected Pyogenic Granuloma (pg) Over the Nose.","authors":"","doi":"10.33140/ijced.08.01.02","DOIUrl":"https://doi.org/10.33140/ijced.08.01.02","url":null,"abstract":"Pyogenic granuloma (PG) is a benign vascular neoplasm, which exhibits several clinical features suggestive of reactive neovascularization. It is common in children and young adults, with a slight predominance in women. PG may occur spontaneously or may result from local trauma. Histologically the lesion of pyogenic granuloma. Proliferating capillaries are often grouped into lobules by dense fibrous bands, hence the synonym lobular capillary hemangioma The lesion is often clutched by an epithelial. On dermoscopy Red homogenous areas intersected by whitish lines – most common in pyogenic granuloma. There are no standard guidelines for the management of PG So invasive or noninvasive approach. Key Message Topical timolol therapy may be the first line of treatment for infected pyogenic granulomas; no adverse systemic effects were reported, over delicate areas like the nose - face on young children, older people, where invasive methods are not preferred, topical timolol may be a therapy option. Objectives to determine whether topical timolol is safe and effective for treating Infected pyogenic granulomas.. Methods We report an A 15-year-old female patient came in with a history of a single, rapidly expanding red lesion on the left side of her nose that had been developing in size for more than a month and was accompanied by minor pain and itching. In addition to unilateral purulent discharge from inside the nose, there was a history of a mild bleeding episode a few days before to consultation. The patient disclosed that she had her nose pierced a month earlier. Suggesting that infected pyogenic granuloma (PG) may coexist. The patient was prescribed timolol twice daily and trimethoprim/polymyxin four times daily with a pyogenic granuloma as the presumptive diagnosis. Results Significant improvement was noted with topical timolol with reduction of the lesion size decrease of bleeding tendency and here symptoms had resolved. Limitations we observed Effects of treatment only in 8 weeks. Conclusion Infected pyogenic granulomas may benefit from topical timolol therapy Longer studies are needed to evaluate resolution and recurrence Rates.","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121848145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Abadie, Faris Oumeish, M. Al-Rubaye, Miriam Al Abadie, Zinah A. A. Sharara
Chronic urticaria is an itchy inflammatory skin condition, also known as hives, weal’s, welts or nettle rash. The main symptom is raised blotchy rash which can be intensely itchy. Its cause is unknown, although it can be triggered by an allergen, physical triggers, underlying health conditions or drugs. Several serious conditions can lead to anaphylaxis which is a medical emergency. Chronic urticaria can be difficult to manage hence there are different approaches for its management. Many still use unlicensed medications to control the condition. We are putting forward a practical approach in the management of this challenging medical problem.
{"title":"Management of Adult Chronic Urticaria: Practical Approach","authors":"M. Abadie, Faris Oumeish, M. Al-Rubaye, Miriam Al Abadie, Zinah A. A. Sharara","doi":"10.33140/ijced.08.01.01","DOIUrl":"https://doi.org/10.33140/ijced.08.01.01","url":null,"abstract":"Chronic urticaria is an itchy inflammatory skin condition, also known as hives, weal’s, welts or nettle rash. The main symptom is raised blotchy rash which can be intensely itchy. Its cause is unknown, although it can be triggered by an allergen, physical triggers, underlying health conditions or drugs. Several serious conditions can lead to anaphylaxis which is a medical emergency. Chronic urticaria can be difficult to manage hence there are different approaches for its management. Many still use unlicensed medications to control the condition. We are putting forward a practical approach in the management of this challenging medical problem.","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131313134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 64 years old female was admitted to hospital due to having repeated blister on skin. Her Dsg1, Dsg3, Bp180, Bp230, VII collagen antibodies were all negative while her ENA-SSA and anti-CCP were positive. Labial glands biopsy revealed that lymphocytes immersed around the glands and a diagnose of Sjögren’s syndrome (SS) was made. Skin biopsy indicated subcorneal pustular with neutrophils immersed and direct immune fluorescence as well as blood and blister fluid culture were negative. Additionally, the patient showed a high expression of IL-6 (18371.09pg/mL) in peripheral blood and blister fluid (19997.89pg/mL).
{"title":"Blister as A Cutaneous Manifestation of Sjogren’s Syndrome Determines IL-6 Antibody to Be A Potential Treatment: A Case Report","authors":"Qiannan Xu, Jie Zheng","doi":"10.33140/ijced.07.02.01","DOIUrl":"https://doi.org/10.33140/ijced.07.02.01","url":null,"abstract":"A 64 years old female was admitted to hospital due to having repeated blister on skin. Her Dsg1, Dsg3, Bp180, Bp230, VII collagen antibodies were all negative while her ENA-SSA and anti-CCP were positive. Labial glands biopsy revealed that lymphocytes immersed around the glands and a diagnose of Sjögren’s syndrome (SS) was made. Skin biopsy indicated subcorneal pustular with neutrophils immersed and direct immune fluorescence as well as blood and blister fluid culture were negative. Additionally, the patient showed a high expression of IL-6 (18371.09pg/mL) in peripheral blood and blister fluid (19997.89pg/mL).","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117072393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ductal carcinoma in situ is a premalignant condition of the breast characteristically discerned through screening mammography and confirmed with pertinent histology. Additionally designated as intra-ductal carcinoma, the lesion may occur as a non-invasive, stage 0 carcinoma breast. Cogent therapy ensures superior prognostic outcomes with > 97% proportionate, extended survival. The premalignant, non-invasive condition exhibits mammary ducts and lobules layered by atypical epithelium wherein stromal invasion is absent. Ductal carcinoma in situ with occasional stromal infiltration emerges as a low grade lesion or high grade, aggressive neoplasm. Multiple lesions or foci of ductal carcinoma in situ articulated within diverse mammary quadrants configure a ‘multi-centric’ neoplasm [1, 2]. Of obscure aetiology, factors contributing to genesis of ductal carcinoma in situ are early menarche’, delayed childbearing, delayed menopause, nulliparous women or family history of carcinoma breast. Hormonal therapy or oestrogen-progestin hormone replacement therapy following menopause for > 5years, genetic mutations of BRCA1 or BRCA2 genes, atypical ductal hyperplasia breast and exposure to radiation or chemicals may contribute to disease emergence. Proportionate occurrence of non-invasive carcinoma is enhanced in women > 45 years [1, 2].
{"title":"The Immured Mammary Metamorphosis-Ductal carcinoma in situ","authors":"Anu Bajaj","doi":"10.33140/ijced.07.01.08","DOIUrl":"https://doi.org/10.33140/ijced.07.01.08","url":null,"abstract":"Ductal carcinoma in situ is a premalignant condition of the breast characteristically discerned through screening mammography and confirmed with pertinent histology. Additionally designated as intra-ductal carcinoma, the lesion may occur as a non-invasive, stage 0 carcinoma breast. Cogent therapy ensures superior prognostic outcomes with > 97% proportionate, extended survival. The premalignant, non-invasive condition exhibits mammary ducts and lobules layered by atypical epithelium wherein stromal invasion is absent. Ductal carcinoma in situ with occasional stromal infiltration emerges as a low grade lesion or high grade, aggressive neoplasm. Multiple lesions or foci of ductal carcinoma in situ articulated within diverse mammary quadrants configure a ‘multi-centric’ neoplasm [1, 2]. Of obscure aetiology, factors contributing to genesis of ductal carcinoma in situ are early menarche’, delayed childbearing, delayed menopause, nulliparous women or family history of carcinoma breast. Hormonal therapy or oestrogen-progestin hormone replacement therapy following menopause for > 5years, genetic mutations of BRCA1 or BRCA2 genes, atypical ductal hyperplasia breast and exposure to radiation or chemicals may contribute to disease emergence. Proportionate occurrence of non-invasive carcinoma is enhanced in women > 45 years [1, 2].","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132087779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pemphigus vegetans is an autoimmune disease characterized by flaccid bullae or pustules that erode to form hypertrophic plaques involving predominantly skin flexures and mucous membranes [1]. We are presenting an unusual case of de novo pemphigus vegetans with extensive involvement of genitals, perianal area, buttocks, nails, oral mucosa, and cerebriform tongue which was initially mistaken for malignancy due to its unusual presentation.
{"title":"De novo Pemphigus Vegetans","authors":"","doi":"10.33140/ijced.07.01.09","DOIUrl":"https://doi.org/10.33140/ijced.07.01.09","url":null,"abstract":"Pemphigus vegetans is an autoimmune disease characterized by flaccid bullae or pustules that erode to form hypertrophic plaques involving predominantly skin flexures and mucous membranes [1]. We are presenting an unusual case of de novo pemphigus vegetans with extensive involvement of genitals, perianal area, buttocks, nails, oral mucosa, and cerebriform tongue which was initially mistaken for malignancy due to its unusual presentation.","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127490392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The zoonotic disease human-monkey pox was first reported in 1970, twelve years after the isolation of monkey pox virus in a laboratory in Denmark in 1958. For decades the disease remained confined to West Africa and the Congo basin. However, during the early 2000s, the disease appeared in the USA and Sudan. On the 31st of May, 2002, the European Centre for Disease Prevention and Control reported the occurrence of 557 confirmed cases worldwide including 321 confirmed from 17 European Union/European Economic Area countries, and 236 confirmed cases occurred in ten non-endemic countries outside the EU/EEA. Most of the cases outside the UK, Canada and United States were linked to travel. However, cases with no travel history nor contact with a patient, animals were also reported. The World health organization could not provide an explanation for this multi-country outbreak because for many cases there was no travel links to an endemic region. The aim of this Continuing Medical Education (CME) paper is to provide a practical overview of human-monkey pox disease.
{"title":"Human-monkey pox disease: An educational CME article","authors":"Aamir Jalal Al-Mosawi","doi":"10.33140/ijced.07.01.10","DOIUrl":"https://doi.org/10.33140/ijced.07.01.10","url":null,"abstract":"The zoonotic disease human-monkey pox was first reported in 1970, twelve years after the isolation of monkey pox virus in a laboratory in Denmark in 1958. For decades the disease remained confined to West Africa and the Congo basin. However, during the early 2000s, the disease appeared in the USA and Sudan. On the 31st of May, 2002, the European Centre for Disease Prevention and Control reported the occurrence of 557 confirmed cases worldwide including 321 confirmed from 17 European Union/European Economic Area countries, and 236 confirmed cases occurred in ten non-endemic countries outside the EU/EEA. Most of the cases outside the UK, Canada and United States were linked to travel. However, cases with no travel history nor contact with a patient, animals were also reported. The World health organization could not provide an explanation for this multi-country outbreak because for many cases there was no travel links to an endemic region. The aim of this Continuing Medical Education (CME) paper is to provide a practical overview of human-monkey pox disease.","PeriodicalId":291908,"journal":{"name":"International Journal of Clinical & Experimental Dermatology","volume":"1997 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128221293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：